Hatteras Venture Partners

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Synaptrix specializes in developing innovative, non-opioid pain management solutions. The company focuses on creating medical devices that employ neuromodulation technology, using electrical or chemical stimulation to alleviate postoperative pain without compromising motor function or touch. This approach aims to provide healthcare professionals with effective, long-lasting alternatives to opioids, promoting rehabilitation and reducing the need for these medications.

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

Endogenex develops a novel endoscopic procedure using pulsed electric fields to regenerate the duodenal mucosa, aiming to improve glycemic control in patients with Type 2 Diabetes.

Founded in 2014, AtaCor Medical specializes in developing innovative cardiac pacing solutions. Its flagship product is the AtaCor EV Temporary Pacing System, which uses an extravascular approach to restore normal heart rhythm temporarily.

iVEAcare specializes in developing advanced neuromodulation therapies to address unmet clinical needs, focusing on chronic diseases. The company creates innovative devices and software that deliver targeted electrical stimulation to specific areas of the brain or spinal cord, aiming to enhance treatment effectiveness and reduce invasiveness.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Cardiosense is a company that focuses on developing a physiological waveform AI platform aimed at creating predictive biomarkers for disease detection and treatment. By mining raw biosignals, Cardiosense provides enhanced visibility into cardiac functions and employs advanced signal processing techniques to identify pre-symptomatic markers of cardiac disease. The company specializes in utilizing non-invasive sensors and proprietary algorithms, which allow healthcare professionals to monitor and analyze cardiac health signals effectively. This innovative approach enables the early detection of diseases, thereby facilitating improved patient care and health tracking.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Boomerang Medical is a female-led bioelectronic medical technology company developing bioelectric neuromodulation therapies to treat autoimmune diseases. The company aims to advance treatment for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis by leveraging bioelectronic medicine to modulate neural pathways involved in immune responses, with the goal of offering more effective and targeted therapies. The approach has drawn regulatory attention, having received FDA breakthrough device designation for Crohn's disease and ulcerative colitis, signaling potential for improved patient outcomes.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

Elligo Health Research, Inc. is a healthcare organization focused on improving the clinical research landscape by bringing research directly to healthcare clinics. Founded in 2016 and headquartered in Austin, Texas, the company utilizes advanced healthcare informatics and electronic health records to enhance patient and physician participation in clinical trials. By enabling physicians to conduct trials within their practices, Elligo eliminates common barriers related to patient enrollment and study delays, while providing essential infrastructure and support. This approach not only accelerates the development of new pharmaceutical, biotechnology, and medical device products but also ensures that patients benefit from access to cutting-edge therapies without the logistical challenges of traditional trials. Elligo's model empowers physicians and offers patients the opportunity to contribute to clinical research, ultimately fostering advancements in healthcare for future generations.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, specializing in the development of surgical instruments for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. Founded in 2014, the company has created a series of disposable surgical tools designed to work alongside general-use endoscopic staplers. These innovative tools help surgeons standardize their techniques, reduce variability, and minimize waste during procedures. By decreasing the number of cartridges needed for each surgery, Standard Bariatrics enables healthcare providers to lower costs while ensuring consistent surgical outcomes.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.

Founded in 2014, AtaCor Medical specializes in developing innovative cardiac pacing solutions. Its flagship product is the AtaCor EV Temporary Pacing System, which uses an extravascular approach to restore normal heart rhythm temporarily.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Elligo Health Research, Inc. is a healthcare organization focused on improving the clinical research landscape by bringing research directly to healthcare clinics. Founded in 2016 and headquartered in Austin, Texas, the company utilizes advanced healthcare informatics and electronic health records to enhance patient and physician participation in clinical trials. By enabling physicians to conduct trials within their practices, Elligo eliminates common barriers related to patient enrollment and study delays, while providing essential infrastructure and support. This approach not only accelerates the development of new pharmaceutical, biotechnology, and medical device products but also ensures that patients benefit from access to cutting-edge therapies without the logistical challenges of traditional trials. Elligo's model empowers physicians and offers patients the opportunity to contribute to clinical research, ultimately fostering advancements in healthcare for future generations.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, specializing in the development of surgical instruments for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. Founded in 2014, the company has created a series of disposable surgical tools designed to work alongside general-use endoscopic staplers. These innovative tools help surgeons standardize their techniques, reduce variability, and minimize waste during procedures. By decreasing the number of cartridges needed for each surgery, Standard Bariatrics enables healthcare providers to lower costs while ensuring consistent surgical outcomes.

Clinipace Inc. is a clinical research organization based in Morrisville, North Carolina, with additional offices in Boulder, Colorado, Buenos Aires, Argentina, São Paulo, Brazil, and various locations in Europe and Asia Pacific. Founded in 2003, the company provides fully integrated clinical research services tailored for venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device companies both in the United States and internationally. Clinipace specializes in a range of therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, and immunology, among others. Its comprehensive suite of services encompasses project management, clinical monitoring, biostatistics, patient recruitment, regulatory affairs, and legal representation, allowing for a collaborative and flexible approach to clinical research that distinguishes it from traditional contract research organizations.

Elligo Health Research, Inc. is a healthcare organization focused on improving the clinical research landscape by bringing research directly to healthcare clinics. Founded in 2016 and headquartered in Austin, Texas, the company utilizes advanced healthcare informatics and electronic health records to enhance patient and physician participation in clinical trials. By enabling physicians to conduct trials within their practices, Elligo eliminates common barriers related to patient enrollment and study delays, while providing essential infrastructure and support. This approach not only accelerates the development of new pharmaceutical, biotechnology, and medical device products but also ensures that patients benefit from access to cutting-edge therapies without the logistical challenges of traditional trials. Elligo's model empowers physicians and offers patients the opportunity to contribute to clinical research, ultimately fostering advancements in healthcare for future generations.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Contego Medical is a medical device company that develops integrated embolic protection technologies for cardiovascular and endovascular procedures. Its product line includes angioplasty balloons and stent delivery catheters that combine treatment and embolic protection, enabling safer interventions in carotid, renal, SVG, and coronary arteries. The company holds FDA clearance for the Paladin Carotid PTA Balloon System with Integrated Embolic Protection, the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection, and the Excipio SV Thrombectomy Device. Founded in 2005, Contego Medical is headquartered in Raleigh, North Carolina, with an additional office in Curitiba, Brazil.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Clinipace Inc. is a clinical research organization based in Morrisville, North Carolina, with additional offices in Boulder, Colorado, Buenos Aires, Argentina, São Paulo, Brazil, and various locations in Europe and Asia Pacific. Founded in 2003, the company provides fully integrated clinical research services tailored for venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device companies both in the United States and internationally. Clinipace specializes in a range of therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, and immunology, among others. Its comprehensive suite of services encompasses project management, clinical monitoring, biostatistics, patient recruitment, regulatory affairs, and legal representation, allowing for a collaborative and flexible approach to clinical research that distinguishes it from traditional contract research organizations.

Clearside Biomedical is a biopharmaceutical company focused on developing treatments for serious eye diseases. It specializes in delivering drugs directly to specific compartments of the eye using its proprietary suprachoroidal injection platform, aiming to restore and preserve vision.

Jumo Health is a New York-based company founded in 2009 that specializes in developing age-appropriate and culturally sensitive educational resources for patients and caregivers. The company collaborates with healthcare providers, manufacturers, and advocacy groups to deliver these resources at critical points in the medical journey, including diagnosis, treatment, and clinical trials. Jumo Health focuses on simplifying complex medical topics through engaging mediums such as comic books, animation, virtual reality experiences, and documentary-style patient stories. By employing visual elements and familiar formats, Jumo Health aims to enhance understanding and accessibility of evidence-based medical literature for diverse audiences.

Clearside Biomedical is a biopharmaceutical company focused on developing treatments for serious eye diseases. It specializes in delivering drugs directly to specific compartments of the eye using its proprietary suprachoroidal injection platform, aiming to restore and preserve vision.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

Clearside Biomedical is a biopharmaceutical company focused on developing treatments for serious eye diseases. It specializes in delivering drugs directly to specific compartments of the eye using its proprietary suprachoroidal injection platform, aiming to restore and preserve vision.

Clinipace Inc. is a clinical research organization based in Morrisville, North Carolina, with additional offices in Boulder, Colorado, Buenos Aires, Argentina, São Paulo, Brazil, and various locations in Europe and Asia Pacific. Founded in 2003, the company provides fully integrated clinical research services tailored for venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device companies both in the United States and internationally. Clinipace specializes in a range of therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, and immunology, among others. Its comprehensive suite of services encompasses project management, clinical monitoring, biostatistics, patient recruitment, regulatory affairs, and legal representation, allowing for a collaborative and flexible approach to clinical research that distinguishes it from traditional contract research organizations.

HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

Embrella Cardiovascular, Inc. is a company based in Malvern, Pennsylvania, focused on developing innovative systems for embolic cerebral protection. Its primary goal is to assist interventionalists in minimizing the incidence of embolic strokes that can occur during cardiovascular procedures. By enhancing the safety and effectiveness of these interventions, Embrella Cardiovascular aims to improve patient outcomes and advance the field of cardiovascular medicine.

SpineAlign Medical, Inc., established in 2005 and headquartered in San Jose, California, specializes in the design, manufacture, and distribution of innovative medical devices for spinal surgery. The company's flagship product, VerteLift, is a nitinol implant used to treat vertebral compression fractures, particularly in osteoporosis patients. SpineAlign focuses on dynamic tools that can be precisely placed and repositioned, supporting vertebral end plates and maintaining lift until bone cement is injected. The company distributes its products in Europe.

Clinipace Inc. is a clinical research organization based in Morrisville, North Carolina, with additional offices in Boulder, Colorado, Buenos Aires, Argentina, São Paulo, Brazil, and various locations in Europe and Asia Pacific. Founded in 2003, the company provides fully integrated clinical research services tailored for venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device companies both in the United States and internationally. Clinipace specializes in a range of therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, and immunology, among others. Its comprehensive suite of services encompasses project management, clinical monitoring, biostatistics, patient recruitment, regulatory affairs, and legal representation, allowing for a collaborative and flexible approach to clinical research that distinguishes it from traditional contract research organizations.